Genome-scale metabolic modelling of the human gut microbiome reveals changes in the glyoxylate and dicarboxylate metabolism in metabolic disorders
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The human gut microbiome has been associated with metabolic disorders including obesity, type 2 diabetes, and atherosclerosis. Understanding the contribution of microbiome metabolic changes is important for elucidating the role of gut bacteria in regulating metabolism. We used available metagenomics data from these metabolic disorders, together with genome-scale metabolic modeling of key bacteria in the individual and community-level to investigate the mechanistic role of the gut microbiome in metabolic diseases. Modeling predicted increased levels of glutamate consumption along with the production of ammonia, arginine, and proline in gut bacteria common across the disorders. Abundance profiles and network-dependent analysis identified the enrichment of tartrate dehydrogenase in the disorders. Moreover, independent plasma metabolite levels showed associations between metabolites including proline and tyrosine and an increased tartrate metabolism in healthy obese individuals. We, therefore, propose that an increased tartrate metabolism could be a significant mediator of the microbiome metabolic changes in metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865
Gut microbiota in human metabolic health and disease
Fan, Y., & Pedersen, O. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0433-9 · Cited by 4,724
Microbiota and SCFA in lean and overweight healthy subjects
Schwiertz, A., Taras, D., Schäfer, K., Beijer, S., Bos, N. A., Donus, C., & Hardt, P. D. (2010) · Obesity · doi:10.1038/oby.2009.167 · Cited by 2,457 · cited 1×
“1 ll OPEN ACCESS interactions within microbial communities (Gu et al., 2019; Magnusdottir et al., 2017; Shoaie et al., 2015).”
Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0
Schellenberger, J., Que, R., Fleming, R. M. T., Thiele, I., Orth, J. D., Feist, A. M., Zielinski, D. C., Bordbar, A., Lewis, N. E., Rahmanian, S., et al. (2011) · Nature Protocols · doi:10.1038/nprot.2011.308 · Cited by 1,835
The gut microbiome in atherosclerotic cardiovascular disease
Jie, Z., Xia, H., Zhong, S.-L., Feng, Q., Li, S., Liang, S., Zhong, H., Liu, Z., Gao, Y., Zhao, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00900-1 · Cited by 1,638 · cited 4×
“In this study, we focused on gut microbial metabolic modeling of three main metabolic disorders, ACVD (Jie et al., 2017; Karlsson et al., 2012), obesity (Le Chatelier et al., 2013b; Qin et al., 2010), and T2D (Karlsson et al., 2013a; Qin et al., 2012a).”
BackgroundMethodInfluentialGut microbiome and serum metabolome alterations in obesity and after weight-loss intervention
Liu, R., Hong, J., Xu, X., Feng, Q., Zhang, D., Gu, Y., Shi, J., Zhao, S., Liu, W., Wang, X., et al. (2017) · Nature Medicine · doi:10.1038/nm.4358 · Cited by 1,501
Symptomatic atherosclerosis is associated with an altered gut metagenome
Karlsson, F. H., Fåk, F., Nookaew, I., Tremaroli, V., Fagerberg, B., Petranovic, D., Bäckhed, F., & Nielsen, J. (2012) · Nature Communications · doi:10.1038/ncomms2266 · Cited by 1,371
A new genomic blueprint of the human gut microbiota
Almeida, A., Mitchell, A. L., Boland, M., Forster, S. C., Gloor, G. B., Tarkowska, A., Lawley, T. D., & Finn, R. D. (2019) · Nature · doi:10.1038/s41586-019-0965-1 · Cited by 1,314
Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome
Perry, R. J., Peng, L., Barry, N. A., Cline, G. W., Zhang, D., Cardone, R. L., Petersen, K. F., Kibbey, R. G., Goodman, A. L., & Shulman, G. I. (2016) · Nature · doi:10.1038/nature18309 · Cited by 1,299
The gut microbiota at the intersection of diet and human health
Gentile, C. L., & Weir, T. L. (2018) · Science · doi:10.1126/science.aau5812 · Cited by 1,049
Cited by
Ricaurte, D., Huang, Y., Sheth, R. U., Gelsinger, D. R., Kaufman, A., & Wang, H. H. (2024) · Nature Microbiology · doi:10.1038/s41564-023-01581-x · Cited by 38
“Furthermore, upregulation of tartrate metabolism by metoprolol could have unintended negative consequences in the context of cardiovascular disease 47 .”
Li, X., Yu, Z., Ye, J., Wang, X., Lin, H., Lei, L., Hu, W., & Luo, Y. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.4c13071 · Cited by 9
Huang, Y., Meng, K., Liu, G., Chen, Z., Han, Y., Yang, P., Zhang, R., & Cai, H. (2025) · Biology · doi:10.3390/biology14091167 · Cited by 7
“Previous studies have linked the upregulation of glyoxy-late and dicarboxylate metabolism with metabolic disorders including obesity, type 2 diabetes, and atherosclerosis [67,68].”
Metadata
- Authors
- Proffitt, C., Bidkhori, G., Lee, S., Tebani, A., Mardinoglu, A., Uhlen, M., Moyes, D. L., & Shoaie, S.
- Venue
- iScience
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 25
- Issue
- 7
- Pages
- 104513
- ISSN
- 2589-0042 (ISSN-L)
- OpenAlex
- W4281770876
- Cited by
- 55
- References
- 12
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genome-scale metabolic modelling of the human gut microbiome reveals changes in the glyoxylate and dicarboxylate metabolism in metabolic disorders. https://app.cochat.ai/papers/10.1016/j.isci.2022.104513
- The paper
- Proffitt, C., Bidkhori, G., Lee, S., Tebani, A., Mardinoglu, A., Uhlen, M., Moyes, D. L., & Shoaie, S. (2022). Genome-scale metabolic modelling of the human gut microbiome reveals changes in the glyoxylate and dicarboxylate metabolism in metabolic disorders. iScience. https://doi.org/10.1016/j.isci.2022.104513
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.